anti-centromeric antibody

The ACA anti-centromere antibody anti-centromere antibody is a DNA protein conjugate that is attached to the centromere of the chromosome, and the fluorescent staining pattern is scattered on the interphase cells. A pair of bright green fluorescence appears on the site of the centromere on the extracellular chromosome. Negative normal people without this antibody, systemic scleroderma patients with high specificity in ACA-positive patients, CREST syndrome in ACA-positive patients (clinical manifestations of soft tissue calcification, Raynaud's phenomenon, esophageal dysfunction, Finger-side hardening, telangiectasia, ACA positive rate of 90%, other connective tissue diseases are rare. Basic Information Specialist classification: growth and development check classification: immunological examination Applicable gender: whether men and women apply fasting: fasting Analysis results: Below normal: Normal value: no Above normal: negative: normal. Positive: No relevant information. Tips: Do not take drugs related to systemic sclerosis, local scleroderma, systemic scleroderma, collagenosis, scleroderma and other related diseases before examination. Normal value The IFAT method (indirect fluorescent antibody method) was negative. Clinical significance Abnormal results: In patients with CREST syndrome, the anti-centromere antibody detection rate is 80% to 90%, which has a diagnostic significance for the syndrome. In addition, anti-centromere antibodies can also be positive in approximately 25% of patients with primary Raynaud's phenomenon (no other symptoms or signs of CREST syndrome). These patients may be early variants or frustrations of CREST syndrome because some of them develop into a typical CREST syndrome in a few years. CREST patients who are anti-centrosome-positive are less likely to have skin and visceral involvement than antibody-negative ones. In patients with systemic progressive sclerosis (PSS), the positive rate of anti-centromere antibodies is 22% to 36%. In addition, there are some patients with SLE, Sjogren's syndrome, RA or Hashimoto's thyroiditis with Raynaud's phenomenon. Anti-centromere antibodies were detected. The people who need to be examined are: patients with related diseases and those with low immunity can be examined. Positive results may be diseases: chronic lymphocytic thyroiditis, pediatric chronic lymphocytic thyroiditis precautions Forbidden before examination: Can not take drugs with systemic sclerosis; local scleroderma; systemic scleroderma; collagenosis; scleroderma and other related diseases, fasting blood test. Requirements for inspection: Note that serum specimens are not contaminated, sent to the test in time, and obey the doctor's request. Inspection process HEP-2 cells were used as substrate to measure ACA by indirect immunofluorescence; anti-topoI (Scl-70) antibody was detected by immunodiffusion method; purified HeLa cell chromosome was used as substrate, and ACA and anti-topoI were detected by immunoblotting. . Not suitable for the crowd Inappropriate population: pregnant women, patients with congenital chromosomal abnormalities. Adverse reactions and risks There are no related complications and hazards.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.